Author Affiliations: Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, Maryland.
The P2Y12 blockers play a critical role in preventing coronary thrombosis1 and are now widely used along with aspirin in patients undergoing coronary stent placement. Despite proven clinical efficacy, the antiplatelet effect of clopidogrel, the most widely used P2Y12 inhibitor, is highly variable as determined by ex vivo platelet function assays. Additionally, studies have demonstrated that high on-treatment platelet reactivity is a major cardiovascular risk factor for subsequent thrombotic events in patients treated with stents.2,3 This has led some to propose that patients who have received stents and were treated with clopidogrel should undergo on-treatment platelet function testing. Yet the degree to which such testing should guide therapy is not yet known.
Gurbel PA, Tantry US. An Initial Experiment With Personalized Antiplatelet Therapy: The GRAVITAS Trial. JAMA. 2011;305(11):1136–1137. doi:10.1001/jama.2011.332
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: